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Long-term proliferating, DHJH-rearranged mouse precursor B-cell lines have previously
been established in serum- and IL-7-containing media from fetal liver, but not from
bone marrow. Serum and stromal cells expose these pre-B cells to undefined factors,
hampering accurate analyses of ligand-dependent signaling, which controls pre-B cell
proliferation, survival, residence and migration. Here, we describe a novel serum-free,
stromal cell-free culture system, which allows us to establish andmaintain pre-B cells not
only from fetal liver, but also from bone marrow with practically identical efficiencies in
proliferation, cloning and differentiation. Surprisingly, recombinant kit-ligand, also called
stem cell factor, produced as a kit-ligand-Fc fusion protein, suffices to replace stromal cells
and serum, provided that it is presented to cultured pre-B cells in an optimal density in
plate-bound, insolubilized, potentially crosslinking form. Additional recombinant CXCL12
and fibronectin have a minor influence on the establishment and maintenance of pre-B
cell lines and clones from fetal liver, but are necessary to establish such cell lines from
bone marrow.
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Introduction
Hematopoietic stem cells (HSCs) and their progeny on the way
to B-lymphocytes—multipotent progenitors (MPP), common lym-
phoid progenitors (CLP), progenitor (pro-pre-B) and precursor
(pre-B) B-lymphocytes—reside within specialized microenviron-
ments, also called niches [1–3]. HSC, MPP, CLP and pre-B cells
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occupy distinct niches. Niches for HSC are found in perivascu-
lar, sinusoidal areas near endothelial cells within bone marrow,
while early B-cell progenitors and precursors have been local-
ized in sub-endosteal regions, near the inner bone surface, in the
neighborhood of osteoblasts [4, 5]. HSC and their progeny up to
pre-BI cells express membrane-bound tyrosine kinase c-kit, which
is involved in the regulation of cell proliferation [6]. Kit-ligand
(kit-L), also called stem cell factor, is provided in the HSC niche
by endothelial cells, in CLP/pro-pre-B- and pre-BI cell niches by
mesenchymally-derived osteoblasts, i.e. non-hematopoietic stro-
mal cells. Such stromal cells have been established as cell lines
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in tissue culture [3]. CLP, pro-pre-B- and pre-BI-cells, express-
ing IL-7 receptors on their surface, require the cytokine IL-7 for
survival and, in costimulation with kit-L for proliferation in their
niches [7–12]. IL-7 is produced by stromal cells [9]. Furthermore,
HSC and their progeny express the chemokine receptor CXCR4
– in fact throughout B-cell development to mature B-cells and
plasma cells [5, 13]. However, the capacity to respond by in vitro
migration to the ligand of CXCR4, CXCL12, is lost, when pro-pre-
B cells develop to pre-BI cells. CXCL12 is abundantly produced
by non-hematopoietic stromal cells [14]. In the bone marrow
niches CXCR4-expressing HSC and their progeny are thought to
be attracted to the CXCL12-producing microenvironments, which
provide specific cytokines for proliferation, survival and develop-
ment, e.g. IL-7 for CLP, pro-pre-B cells and pre-BI cells. When
these interactions cease to function for attracting pre-BI cells into
IL-7-producing niches, pre-BI cells loose the stimulatory influ-
ence of IL-7, are induced to rearrange VDJ-genes within IgH- and
IgL-chain loci and develop to pre-BII cells and immature sIgM+
B-cells [7, 8].
It has long been known that mouse precursor B cells of fetal
liver, defined as CD19+c-kit+IL-7R+ DHJH/DHJH-rearranged pre-
BI cells, can be cloned and maintained proliferating in vitro at
this stage of B-cell differentiation for weeks and months in co-
cultures of irradiated messenchymal stromal cells and IL-7 in
serum-containing medium [7–10]. Proliferation of pre-BI cells is
stimulated through c-kit [11] and the IL-7 receptor [7], while sur-
vival is maintained by IL-7 alone [7, 12]. While fetal liver-derived
pre-BI cells proliferate for many weeks [8, 10] without chang-
ing their state of differentiation, bone marrow-derived pre-BI cells
have been found to cease proliferation after two or three weeks
on stromal cells and IL-7.
A drawback of this culture system has been, that pre-BI cells
might receive a variety of molecularly undefined, hence, exper-
imentally uncontrolled signals from serum and stromal cells.
Such signals might hamper an accurate in vitro cell analysis of
other, additional co-stimulatory requirements. It has also lim-
ited the elucidation of ligand-receptor-dependent signaling path-
ways and, thus, regulations of gene expression involved in prolif-
eration, survival and differentiation. A previous study reported
a serum- and stromal cell-free culture system for pre-BI cells
[12]. However, in the initial phase of culture, high cell densi-
ties (at 1×105/mL) were necessary to establish pre-B cell lines
in vitro, cells hardly proliferated during the initial weeks in cul-
ture, and it was not possible to clone pre-BI cells, as it was later
achieved on stromal cells in serum- and IL-7-containing culture
[8].
Here, we report the establishment of a novel culture sys-
tem for pre-BI cells not only from fetal liver, but also from
bone marrow. It allows pre-BI cell cloning at maximum effi-
ciencies and high-rate, long-term proliferation of all pre-BI cells
in completely serum-free cultures [15], stimulated by immobi-
lized recombinant kit-L in combination with recombinant, soluble
IL-7.
Results and discussion
Fetal liver-derived pre-BI cell culture on immobilized
kit-L-Ig
Kit-L is produced in two forms by alternative splicing of the
same RNA transcript, allowing the production of a secreted and
a membrane-bound form [6, 16]. Both forms are produced by
fibroblasts and endothelial cells, and by the stromal cells used
in pre-BI cell cultures. We generated kit-L-Ig fusion proteins and
coated plastic tissue culture plates at different concentrations with
them to mimic membrane-bound forms of kit-L that are normally
present on stromal cell surface membranes, and then tested the
proliferation of established mouse fetal liver-derived pre-BI cell
lines (Fig. 1A). Together with IL-7, plate-bound kit-L-IgFc stimu-
lated long-term proliferation in a dose-dependent manner. Pro-
liferation was maximal, and almost as efficient as on stromal
cells, when tissue culture plates were coated at 1 μg/mL. Lower,
and also higher concentrations were less stimulatory. The solu-
ble form of kit-L-Ig, or soluble recombinant kit-L did not stimu-
late pre-BI cell proliferation (Fig. 1A). Microscopic observation
showed pre-BI cells on plate-bound kit-L-Ig growing attached
to the bottom of the plate, similar to those on stromal cells,
while those cultured in the presence of soluble form of kit-L-Ig
or recombinant kit-L were floating in medium (Fig. 1B). These
results suggest that plate-immobilized kit-L, binding to c-kit recep-
tors on pre-BI cells, crosslinks these receptors for stimulation of
proliferation. Too low, or too high densities of kit-L are subop-
timal for this stimulation, suggesting, that an optimal pattern
of c-kit receptor crosslinking provided optimal stimulation of
proliferation.
Next, we replaced serum in the culture medium with puri-
fied, Fe3+ -complexed transferrin and BSA, coated with defined
lipids, that have been found to replace serum for maintaining
LPS-stimulated murine B-cells in culture [15]. Previously, differ-
ent serum-free media had been used to culture pre-B cells [12].
This serum-free medium, IL-7 and an optimal concentration of
plate-immobilized kit-L allowed the same number of pre-B cells
to proliferate comparably or, two-fold higher, if any, at day 26 of
culture (5×108 vs. 1×109) to conventional culture condition with
serum-containing medium on OP9 (Fig. 1C).
In addition, we also added fibronectin and CXCL12.
Fibronectin, an extracellular matrix glycoprotein present in serum,
is known to play multifunctional roles in cell adhesion, growth
and differentiation. We found, that the soluble form of fibronectin
together with CXCL12 [17] improved continued pre-BI cell prolif-
eration, again with little significant difference in long-term culture
(at day 26 of proliferation 3×109 vs. 1×109 cells, Fig. 1C). Such
pre-BI cells could be maintained at least 3 months without any
apparent changes in rates of proliferation, or in their state of dif-
ferentiation (data not shown). Initial phase of culture on kit-L-Ig
in combination with fibronectin and CXCL12 in serum-free condi-
tion improved pre-BI cell proliferation two fold higher than that
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Figure 1. Pre-BI cell cultures on immobilized kit-L-Ig. Fetal liver-derived pre-BI cell lines were cultured in serum-containingmedium or serum-free
conditionmedium including IL-7. (A) Cell numbers at day 4 of culture in serum-containingmedium on immobilized kit-L-Ig (◦), with soluble kit-L-Ig
() or recombinant kit-L () at different concentrations (n= 4 each). The number of live cells after culture was determined by flow cytometry. Plate-
coated kit-L-Ig, detected by colorimetric assay (dashed line, ♦). (B) Microscopic observation of pre-BI cell lines at day2 cultured on immobilized
kit-L-Ig (left), in soluble form of kit-L-Ig (middle) or recombinant kit-L (right). Scale bars indicate 20 μm. Images are from a single experiment
representative of at least three independent experiments (C) Kinetics of pre-BI cell proliferation during long-term culture in serum-containing
mediumwith OP9 (♦), or in serum-free conditionmediumwith (•) or without (◦) CXCL12 and fibronectin (FN) on immobilized kit-L-Ig. Accumulated
cell number counted by flow cytometry at each time point on passage is shown. Data are shown as mean+/– SD and are from a single experiment
representative of at least three independent experiments. Statistical analysis was performed by t-test; * = p<0.05, ** = p<0.01. N.S. = not significant.
cultured on kit-L-Ig alone and yielded similar number of pre-BI
cells as that on OP9 cells in serum-containing condition (Support-
ing Information Fig. 1).
Flow cytometric analysis showed that pre-BI cells proliferating
on plate-bound kit-L-Ig in serum-free medium were sIg−CD19+IL-
7R+AA4.1(CD93)+CD24+, but had reduced levels of surface c-kit
(CD117) expression, compared with cells proliferating on OP9
stromal cells in serum-containing medium (Supporting Informa-
tion Fig. 2A). In addition, expression of surface CXCR4 and of
surrogate light chain were significantly higher in pre-BI cells
maintained on plate-bound kit-L-Ig compared with those on OP9
(Supporting Information Fig. 2A). This elevated CXCR4 expres-
sion is possibly due to a loss of receptor down-modulation
through CXCL12 produced by OP9, because the addition of
CXCL12 in pre-BI cells on plate-bound kit-L-Ig lowered the
CXCR4 expression level comparable to that of pre-BI cells main-
tained on OP9 (Supporting Information Fig. 2B and C). Simi-
larly, higher surface expression of surrogate light chain might be
explained by loss of down-modulation through the interaction
with the possible ligand on stromal cells, such as heparin sulfates
[18, 19].
Serum-free, stromal cell-free cultures of bone
marrow-derived pre-BI cells ex vivo
To test if these serum- and stromal cell-free culture conditions
could also be used to establish pre-BI cell lines and clones from
primary pre-BI cells of fetal liver, or of bonemarrow ex vivo, FACS-
enriched CD19+c-kit+ cells from normal mice were cultured in our
serum-, stromal cell-free culture conditions. Consistent with cul-
tures of fetal liver-derived pre-BI cell lines (Fig. 1A–C), primary
CD19+c-kit+ cells also proliferated in serum-free medium contain-
ing IL-7, CXCL12 and fibronectin on plate-bound kit-L-Ig, with no
significant differences to cells cultured on OP9 in serum-contained
medium (Fig. 2A).
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Figure 2. Serum-free, stromal cell-free culture of pre-BI cells ex vivo. FACS-purified bone marrow-derived CD19+ckit+ cells were cultured in
culture medium with IL-7 in serum-containing condition on OP9 or in serum-free condition on immobilized kit-L-Ig with or without CXCL12
and/or fibronectin. (A) Cell numbers at day 4 of culture at each culture condition is shown (n = 4 each). The number of live cells after culture was
determined by flow cytometry. (B) Proliferation kinetics during long-term culture (n = 3) and (C) cloning efficiencies at 7 days culture of purified
bone marrow-derived CD19+ckit+ cells in serum-containing medium on OP9 (♦), or in serum-free medium with (•) or without (◦) CXCL12 and
fibronectin on immobilized kit-L-Ig. In (B), accumulated cell number determined by flow cytometry at each time point on passage is shown. In (C),
pre-B-cell colonies, consisting of more than 100 cells, were scored by a microscope and the frequency of clonable pre-BI cells was calculated by
counting negative wells according to Poisson’s distribution. Pre-BI cells cultured in serum-free medium with soluble kit-L-Ig are indicated as open
squares (). (D) The number of IgM+kL+ cells differentiated from pre-BI-cells maintained on indicated culture condition (n = 4). Data are shown
as mean+/– SD and are from a single experiment representative of at least three independent experiments. A two-tailed paired Student t-test was
used for statistical analysis. * = p <0.05, ** = p<0.01. N.S. = not significant.
Notably, cell lines from primary cells of bone marrow could
only be established and maintained for long periods of time
cultured in serum-free medium with IL-7, CXCL12 and fibronectin
on plate-bound kit-L-Ig, but not on OP9 in serum-containing
medium (Fig. 2B).
Routinely, CD19+c-kit+CD93+sIg− pre-BI cells, isolated by
FACS ex vivo from fetal liver have been cloned at high efficiencies
on OP9 and IL-7 in serum-containing medium culture [8]. There-
fore, we tested the efficiency of cloning of such primary pre-BI
cells in our serum- and stromal cell-free, plate-immobilized kit-L-
Ig-stimulated, IL-7-, fibronectin and CXCL12-containing cultures.
Limiting dilution assays revealed that the efficiency of cloning of
pre-BI cells on plate-bound kit-L-Ig in the presence of CXCL12 and
fibronectin was 1 in 6 cells, and, therefore, almost the same as that
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found with cells cultured on OP9 in serum-containing medium, i.e.
1 in 5 cells. The frequency of cloningwas two-fold lower in cultures
not containing CXCL12 and fibronectin, showing the importance
of these molecules. Pre-BI cell cloning efficiency was much lower
in cultures containing the soluble form of kit-L-Ig, i.e. 1 in less
than 100 cells (Fig. 2C).
Finally, CD19+c-kit+ pre-BI cells proliferating under the new
serum- and stromal cell-free culture conditions were induced
to differentiate by the removal from plate-immobilized kit-L-Ig
and IL-7 to IgM+ immature B-cells with frequencies equal to as
those previously cultured on OP9 in serum-containing medium
(Fig. 2D).
Our results show that a pre-BI cell niche in mouse fetal liver
needs no more than IL-7 and immobilized, probably membrane-
bound kit-ligand, both provided by the microenvironment, to
control proliferative expansions. It is surprising, that these con-
ditions also allow single cell cloning at nearly equally high
efficiencies of plating. Hence, stromal cells do not supply any
undefined “filler effect” for fetal liver-derived pre-B cells, which
thymus cells do for the cloning of mature, LPS-stimulated B-
cells [20]. In contrast, our data showed that fibronectin and
CXCL12 have a stronger influence to pre-B cells in bone mar-
row than in fetal liver. Thus, bone marrow-derived pre-B cells
need these additional environmental factors to initiate prolifer-
ation. This may be a reflection of the capacity of pre-B cells to
home to bone marrow niches, and to reside in them, controlled
by additional interactions, such as CXCL12-CXCR4, with this
microenvironment.
Our new culture system, including CXCL12 and fibronectin,
does not allow cloning and proliferation of Pax5-deficient,
CLP/MPP-like progenitors [21] with comparable efficiencies (Sup-
porting Information Fig. 3). Additional factors for initiation of
growth and for long-term proliferation and survival of CLP, pro-
vided in vitro by OP9 stromal cells, and in vivo in CLP niches by
the microenvironment, defining the differences in growth require-
ments between these earlier progenitors and pre-BI cells in early
B-cell development might become identifiable with the help of our
new culture system.
We expect that a plate-immobilized form of human kit-L in
serum-free cultures will provide comparable stimulatory effects
for human pre-BI cells. This, in turn, might allow a renewed
search for the elusive human, IL-7-like pre-B cell cytokine. In
turn, it would set the experimental condition to analyze muta-
tions in human progenitor and pre-B cells, which lead to immun-
odeficiencies or to malignant transformations in early B-cell
development.
In conclusion, we have established a stromal cell-free, serum-
free culture system for primary CD19+c-kit+ cells as well as pre-BI
cell lines, which is functionally equivalent to previously used cul-
tures on stromal cells. These conditions also allow us to establish
pre-BI cell lines and clones from bone marrow, which has pre-
viously not been possible. Hence, fetal liver and bone marrow
appear to have functionally distinct niches, in which they prolif-
erate. Besides, this simple culture platform will be of technical
advantage to allow drug-based selection, free of drug-resistant
stromal cells for the generation of gene-modified pre-BI cells,
as well as useful for studies of intracellular signaling pathways,
controls of gene expression and functional responses of single
pre-BI cells in defined, ligand-controlled ways.
Materials and methods
Animals
C57BL/6 mice (Charles River, Germany) were maintained
under specific pathogen-free (SPF) conditions. All experiments
were performed according to German guidelines for animal
experiments.
Vector construction, production and purification of
kit-L-Ig
We designed two gene fragments of double strand DNA nucleotide
sequences generated by artificial gene synthesis (Life technolo-
gies), consisting of the mouse immunoglobulin kappa chain signal
peptide (METDTLLLWVLLLWVPGSTGD) followed by the extra-
cellular domain of mouse kit-L (1-164 a.a of mature peptide from
NCBI Reference Sequence: NP 038626.1), and the constant region
of mutant human IgG1 (non-lytic form, 6–232 a.a from Gen-
Bank: AEV43323.1, where Leu at position 20 was mutated to
Glu, and Glu, Lys, Lys at position 103, 105, 107, respectively,
was mutated to Ala) [22] with 3xGGGGS linker sequences at the
N-terminus. These fragments were inserted into the cloning site of
a mammalian expression vector pCAGGS [23] by In-fusion cloning
(Clonetech) to generate kit-L-Ig expression vector. The plasmid
(30 μg) was transfected into 293T cells by 90 μg of PEI-MAX
(Polyscience) for the transient overexpression to produce kit-L-Ig
fusion proteins in the culture supernatant, followed by column
purification with protein A. The proteins after elution with 0.1M
glycine buffer (pH 2.7) were immediately neutralized with 1M
Tris-EDTA buffer (pH 9.0), and a part of them was subjected
to SDS-PAGE followed by the staining with Coomasie Brilliant
Blue G-250 (Supporting Information Fig. 4). After the confirma-
tion of purity (>90%), eluted fractions were dialyzed with PBS
and sterilized by 0.22 μm filter. Protein concentration was deter-
mined by Bradford assay (Bio-rad) using NanoDrop 1000 (Thermo
Scientic).
The measurement of plate-coated kit-L-Ig
Different concentrations of kit-L-Ig in PBS 50 μL were coated on
96-well plate for 2 h at RT. After washing 3 times with 200 μL
of PBS/0.05%tween-20, 100 μL of PBS/0.1%BSA solution was
added and incubated for 1o/n at 4ºC. After removal of blocking
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buffer, plates were incubated with 100 μL of HRP-conjugated
goat anti-human IgG (Santacruz, sc-2453) at 1 μg/mL for 1 h
at RT. Following extensive wash 5 times with PBS/0.05%tween-
20, 100 μL of 1xTMB solution (ebioscience) was added and the
absorbance at 450 nm was measured by microplate reader Model
680XR (Bio-rad).
Cytokines and medium
Culture medium was prepared in Iscove’s Modified Dulbecco’s
Medium (IMDM) supplemented with 0.036 mM NaHCO3/50 μM
β-mercaptoethanol/0.03% primatone/1x kanamycin/1x non-
essential amino acid (Gibco) including 1 ng/mL IL-7 (Peprotech)
together with 2% fetal bovine serum (FBS) or 1 mg/mL of de-
lipified BSA (Sigma), 10 μg/mL of human transferrin (Sigma)
and 0.005%Fatty-acid Supplement (Sigma) (designated as serum-
free conditioned medium). In some experiments, 100 ng/mL of
CXCL12α (Peprotech) and/or 10μg/mL Fibronectin (Sigma) were
added in culture.
Cell culture
Fetal liver-derived pre-BI cell lines or bone marrow-derived
CD19+ckit+ cells isolated by FACS from 6–8wks-old C57BL/6
mice, or Pax5-deficient proB-cell lines were plated at 1×104/mL
in 200 μL of serum-containing medium or serum-free condition
medium, including 1 ng/mL IL-7 on 96-well flat-bottom plates.
OP9 cells were pre-coated at 1×104 cells/cm2 one day before
30-Gy irradiation. Kit-L-Ig proteins were pre-coated at different
concentration ranging from 1 ng/mL to 10μg/mL by tenfold serial
dilution by the incubation at room temperature for at least 2 h,
followed by wash 3 times with PBS before cell culture. Kit-L-Ig
or recombinant kit-L (Peprotech, #250-03) were also added in
culture as soluble form at the same concentration as that used
for immobilization of kit-L-Ig. Cells were passaged every 3 or 4
days to another wells freshly pre-coated with OP9 cells or kit-L-Ig,
and cell proliferation was evaluated at each time point after cul-
ture by counting the number of live cells determined as negative
for propidium iodide by LSR II (BD) analyzer. Data analysis was
performed with FlowJo (Treestar).
Limiting dilution assay
FACS-sorted CD19+ckit+ cells were plated at 4 different number
of cells by threefold serial dilution from 20 cells to 0.7 cells in 24
wells each on 96-well plates coated with irradiated OP9 cells in
serum-containing medium or with 1μg/mL of kit-L-Ig in serum-
free condition medium with or without CXCL12 and fibronectin.
After 7 days of culture, pre-B cell colonies, consisting of more
than 100 cells, was scored by a microscope and the frequency of
clonable pre-BI cells was calculated by counting negative wells
according to Poisson’s distribution.
Statistics
Statistical analyses were performed by using a two-tailed paired
Student t test. P-value of <0.05 was considered statistically
significant.
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